The FDA doesn't review the safety and efficacy of compounded products, which are custom-made alternatives to brand-name drugs designed to meet a specific patient's needs. Compounded products can also be produced when brand-name treatments are in shortage.
Semaglutide is currently in shortage, according to the FDA.
Durbin and Marshall said advertisements for brand-name GLP-1 medications include "significant risk disclosures to patients about side effects and contraindications, including warnings about potential gallbladder, pancreas, vomiting, diarrhea, and other implications."